Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has a good chance at potentially staging a comeback with its other pipeline drug pociredir, which is being developed in a phase 1b study for the treatment ...

After a six-month wait, Fulcrum Therapeutics’ sickle cell disease (SCD) plans are back on track after the FDA lifted a hold on the biotech’s candidate.. The regulator instigated the full ...

Fulcrum Therapeutics, Inc. ― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ― ― Completed enrollment in 6 mg and 2 mg dose cohorts of the ...

Fulcrum Therapeutics, Inc. (FULC) has been on a downward spiral lately with significant selling pressure. After declining 32.6% over the past four weeks, the stock looks well positioned for a ...

Earnings Call Insights: Fulcrum Therapeutics ... The company ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities, down from $241 million at year-end 2024.

By 12:45 p.m., Fulcrum shares had dropped 51%, to $6.27, giving the company a market capitalization of $387 million.

Fulcrum Therapeutics reports financial results, drug trial updates, and announces a conference call on February 25, 2025. Quiver AI Summary. Fulcrum Therapeutics, Inc. has announced its financial ...

Fulcrum Therapeutics, Inc. (FULC) shares ended the last trading session 20.6% higher at $12.30. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...